Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

402 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

NCT00812019

Influenza

COMPLETED PHASE1

H7N9 Mix and Match With MF59 in Healthy Adults

NCT01938742

Influenza

COMPLETED PHASE2

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945

Prophylaxis of A/H3N2v Influenza

COMPLETED PHASE1

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

NCT04789577

Influenza, Human

COMPLETED PHASE2

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

NCT01596725

Influenza (Pandemic)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

H7N9 Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

H7N9c low dose with adjuvant

Group Type EXPERIMENTAL

H7N9c low dose with adjuvant

Intervention Type BIOLOGICAL

Group B

H7N9c medium dose with adjuvant

Group Type EXPERIMENTAL

H7N9c medium dose with adjuvant

Intervention Type BIOLOGICAL

Group C

H7N9c high dose with adjuvant

Group Type EXPERIMENTAL

H7N9c high dose with adjuvant

Intervention Type BIOLOGICAL

Group D

H7N9c high dose without adjuvant

Group Type EXPERIMENTAL

H7N9c high dose without adjuvant

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H7N9c low dose with adjuvant

Intervention Type BIOLOGICAL

H7N9c medium dose with adjuvant

Intervention Type BIOLOGICAL

H7N9c high dose with adjuvant

Intervention Type BIOLOGICAL

H7N9c high dose without adjuvant

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adult subject ages 18-64 years.
2. Individuals willing to provide written informed consent
3. Individuals in good health.
4. Individuals who can comply with study procedures and follow-up.

Exclusion Criteria

1. Individuals with history of cognitive or behavioral impairment or psychiatric disease,
2. Individuals unable to understand and follow study procedures,
3. History of significant illness,
4. History of chronic medical condition or progressive disease,
5. Allergy to any vaccine component or adverse event related to a vaccine component,
6. Impairment/alteration of the immune system,
7. Presence of progressive or severe neurological disorder,
8. Pregnant or breast-feeding,
9. Female of Child-bearing potential unwilling to use acceptable method of birth control,
10. Presence of medically significant cancer,
11. Receipt of investigational product within 30 day prior to entry into the study,
12. History of previous or suspected illness from avian flu caused by H7N9 virus,
13. History of H7 vaccination,
14. Body temperature of greater than or equal to 38.0°C (100.4◦F) and/or acute illness within 3 days of intended study vaccination,
15. Receipt of any flu vaccination 2 weeks before study entry or 4 weeks after study vaccination,
16. Receipt of any vaccination 2 weeks before study entry or 4 weeks after study vaccination,
17. History of drug or alcohol abuse within the past 2 years,
18. Body Mass Index (BMI) greater than or equal to 35kg/m2,
19. Individuals conducting the study or their immediate family members.

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes